According to the Complaint, Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide.

The Complaint alleges that throughout the Class Period, Defendants made materially false and misleading statements regarding the Company’s business, operations and compliance policies. Specifically, the Complaint alleges Defendants made false and/or misleading statements and/or failed to disclose that: (i) Boston Scientific’s surgical mesh products indicated for the transvaginal repair of POP were unsafe; (ii) accordingly, Boston Scientific’s continued marketing and sales of these devices in the United States was unlikely to be sustainable; (iii) separately, the Company had sold vaginal mesh implants containing counterfeit or adulterated resin products imported from China; (iv) the foregoing conduct subjected the Company to a heightened risk of regulatory scrutiny and/or government investigations; and (v) as a result, the Company’s public statements were materially false and misleading at all relevant times.

On June 18, 2019, the Court issued an Order transferring the case to the District Court for the District of Massachusetts. The Court issued an Order appointing Lead Plaintiff and Counsel on July 17. Lead Plaintiff voluntarily dismissed the claims on September 20, 2019.